कंपनी का अवलोकन
Damora Therapeutics, Inc. (GLTO) operates as a clinical-stage biotechnology entity focused on the development of molecule therapeutics designed to treat fibrosis, cancer, inflammation, and other related diseases. The company specifically concentrates on creating preclinical small molecule dual inhibitors, such as GB3226 which targets ENL-YEATS and FLT3, as well as GB1211, an oral small molecule formulation. This organization functions within the broader Healthcare sector and specifically the Biotechnology industry, environments characterized by high research expenditures and long development cycles before product commercialization. With a market capitalization of $1.73B, an annual revenue figure that is not currently disclosed in TTM terms, and a workforce of 5 employees, the company presents a unique valuation profile common in early-to-mid stage biotech firms. The substantial market cap relative to the minimal employee count suggests that the company's valuation is driven primarily by the potential future value of its drug pipeline rather than current operational scale or cash flow generation.
वित्तीय स्वास्थ्य
Damora Therapeutics reports a Net Income (TTM) of $-15,844,000 and an EBITDA of $-11,862,000, while its Revenue (TTM) is not available for public disclosure. The significant negative gap between the undisclosed revenue and the substantial net losses indicates a cost structure dominated by Research and Development expenses, which is typical for clinical-stage biotechnology companies prioritizing asset development over immediate profitability. The company's Free Cash Flow stands at $-7,066,875, reflecting a capital-intensive business model where cash is consumed rapidly to fund clinical trials and preclinical studies, thereby limiting current financial flexibility for external expansion. Profitability metrics are non-existent, with a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, indicating that the company has not yet achieved a break-even point in its current operational phase. In terms of leverage, the company holds $7.61M in cash against a total debt obligation of $72,000, resulting in a Debt to Equity ratio of 0.90, which suggests a balance sheet that is heavily reliant on equity financing rather than traditional debt instruments. Despite the low absolute debt, the current ratio of 3.73 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, although the liquidity is largely tied up in cash reserves rather than liquid inventory. Furthermore, the Return on Equity stands at -109.5% and the Return on Assets is -43.5%, revealing that management is currently deploying capital to generate losses rather than returns, a standard metric for pre-revenue entities burning cash to achieve future commercial milestones.
मूल्यांकन आकलन
The valuation metrics for Damora Therapeutics are complex due to the lack of earnings, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -30.20. The negative forward P/E implies that the market is pricing in future earnings growth that has not yet been realized, as the denominator for the ratio remains negative or undefined based on current projections. The Price to Book ratio is recorded at 5.71, indicating that the market values the company at a premium of 5.71 times its book value, a multiple often seen in biotech firms where intangible assets like intellectual property and pipeline potential outweigh tangible book value. Alternative valuation metrics such as Price to Sales, which is N/A, and an EV/EBITDA of -2.33 further highlight the reliance on non-earnings-based valuation models since traditional profitability ratios are inapplicable. The stock has exhibited significant volatility over the past year, trading between a 52-Week High of $38.33 and a 52-Week Low of $2.01. Without a specific current price provided in the facts to calculate a precise percentage, the range demonstrates extreme price discovery typical of speculative biotechnology assets. The Beta value of 1.57 indicates that the stock's price volatility is 57% higher than the broader market, suggesting high sensitivity to market movements and specific sector sentiment.
Growth & Income
Damora Therapeutics reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), reflecting the company's status as a pre-revenue or early-stage entity where historical growth rates are not yet established. Since the company has not generated positive earnings, it does not distribute dividends, resulting in a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company follows a capital allocation strategy where all available resources are reinvested into the development of its therapeutic molecules rather than being distributed to shareholders. The overall growth and income profile is characterized by a lack of current income generation and undefined historical growth rates, which necessitates a reliance on future clinical success and regulatory approvals to unlock value.